Characteristics of IPV responders versus nonresponders
Characteristic . | Responder, n = 210 . | Nonresponder, n = 9 . | OR . | P . |
|---|---|---|---|---|
| Median age, y (range) | 21.9 (0.2-69) | 44.4 (10-61.5) | 0.94 | .01 |
| Age younger than 18 y, no. (%) | 107 (44.0)* | 1 (10.0) | 7.08 | .07 |
| Sex, no. male (%) | 150 (61.7) | 5 (50.0) | 1.61 | .46 |
| Donor, no. (%) | ||||
| HLA-matched related | 157 (64.6) | 5 (50.0) | 1.82 | .35 |
| HLA-mismatched related | 22 (9.1) | 2 (20.0) | 0.39 | .26 |
| Unrelated | 64 (26.3) | 3 (30.0) | 0.83 | .80 |
| Graft type, no. (%) | ||||
| cBMT | 73 (30.0) | 1 (10.0) | 3.86 | .20 |
| cPBSCT | 12 (4.9) | 0 (0) | — | — |
| TCD-BM | 127 (52.3) | 7 (70.0) | 0.46 | .28 |
| TCD-PB | 30 (12.4) | 2 (20.0) | 0.56 | .48 |
| Cord blood | 1 (0.4) | 0 (0) | — | — |
| TBI regimen, no. (%) | 174 (71.9) | 10 (100) | — | — |
| DLI, no. (%) | 54 (22.2) | 3 (30.0) | 0.67 | .57 |
| Rituximab, no. (%) | 21 (8.6) | 2 (20.0) | 0.38 | .24 |
| Grade II-IV acute GVHD, no. (%) | 41 (16.9) | 0 (0) | — | — |
| Chronic GVHD, no. (%) | 34 (14.0) | 3 (30.0) | 0.38 | .18 |
Characteristic . | Responder, n = 210 . | Nonresponder, n = 9 . | OR . | P . |
|---|---|---|---|---|
| Median age, y (range) | 21.9 (0.2-69) | 44.4 (10-61.5) | 0.94 | .01 |
| Age younger than 18 y, no. (%) | 107 (44.0)* | 1 (10.0) | 7.08 | .07 |
| Sex, no. male (%) | 150 (61.7) | 5 (50.0) | 1.61 | .46 |
| Donor, no. (%) | ||||
| HLA-matched related | 157 (64.6) | 5 (50.0) | 1.82 | .35 |
| HLA-mismatched related | 22 (9.1) | 2 (20.0) | 0.39 | .26 |
| Unrelated | 64 (26.3) | 3 (30.0) | 0.83 | .80 |
| Graft type, no. (%) | ||||
| cBMT | 73 (30.0) | 1 (10.0) | 3.86 | .20 |
| cPBSCT | 12 (4.9) | 0 (0) | — | — |
| TCD-BM | 127 (52.3) | 7 (70.0) | 0.46 | .28 |
| TCD-PB | 30 (12.4) | 2 (20.0) | 0.56 | .48 |
| Cord blood | 1 (0.4) | 0 (0) | — | — |
| TBI regimen, no. (%) | 174 (71.9) | 10 (100) | — | — |
| DLI, no. (%) | 54 (22.2) | 3 (30.0) | 0.67 | .57 |
| Rituximab, no. (%) | 21 (8.6) | 2 (20.0) | 0.38 | .24 |
| Grade II-IV acute GVHD, no. (%) | 41 (16.9) | 0 (0) | — | — |
| Chronic GVHD, no. (%) | 34 (14.0) | 3 (30.0) | 0.38 | .18 |
—indicates not applicable. Additional abbreviations are explained in Tables 1 and 2.